TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26421426

Group type: EXPERIMENTAL
Intervention: Combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day administered D1-14 every 21 days)
Number of subjects: 92
Study: 26422550

Group type: EXPERIMENTAL
Intervention: Non-elastic taping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soft brace
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All three methods (kinesiotaping, non-elastic taping, soft brace)
Number of subjects: 40
Study: 26423260

Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin (with potential escalation to 10 mg)
Number of subjects: 2
Study: 26423374

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg plus Elbasvir 50 mg once daily for 12 weeks
Number of subjects: 218
Study: 26423388

Group type: EXPERIMENTAL
Intervention: Gestational fasting plasma glucose (FPG) in nonobese mothers
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Gestational fasting plasma glucose (FPG) in obese mothers
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Prepregnancy adiposity
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Gestational fasting plasma glucose (FPG)
Number of subjects: 937
Study: 26423389

Group type: COMPARATOR
Intervention: High-caloric mixed meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hepatic γATP, inorganic phosphate (Pi), and fat content (hepatocellular lipids) measured with (31)P/(1)H magnetic resonance spectroscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole-body insulin sensitivity (M value) assessed with hyperinsulinemic-euglycemic clamps
Number of subjects: 30
Study: 26423721

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment based on Clinical Dementia Rating (CDR) scale (MCI-CDR)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment based on neurocognitive battery (MCI-NC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MCI-CDR, MMSE, and Lawton IADL score
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MCI-NC, CDR sum of boxes, MMSE, and Lawton IADL score
Number of subjects: 102
Study: 26423734

Group type: EXPERIMENTAL
Intervention: Higher intakes of fruits and vegetables
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher intakes of β-carotene
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher intakes of vitamin C
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher intakes of α-tocopherol
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher intakes of EPA
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher intakes of DHA
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Higher intakes of ALA
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentration
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Supplements (β-carotene, vitamin C, α-tocopherol)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 86
Study: 26423739

Group type: EXPERIMENTAL
Intervention: Children's food neophobia
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Children's sensory behaviors (SBs)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 249
Study: 26423749

Group type: EXPERIMENTAL
Intervention: ≥125mcg/day of levothyroxine
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ≥200mcg/day of levothyroxine
Number of subjects: 500
Study: 26423811

Group type: EXPERIMENTAL
Intervention: Panobinostat (20 mg) three times per week every other week for 8 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Panobinostat (20 mg)
Number of subjects: 15
Study: 26423856

Group type: EXPERIMENTAL
Intervention: Whole body cooling
Number of subjects: 180
Study: 26423989

Group type: EXPERIMENTAL
Intervention: Maraviroc (600 mg twice daily)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 26424330

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 3152
Study: 26424605

Group type: EXPERIMENTAL
Intervention: Modified DENV-2 strain DEN2Δ30
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dengue human infection model (DHIM) developed by Walter Reed Army Institute of Research (WRAIR)
Number of subjects: 30
Study: 26425874

Group type: EXPERIMENTAL
Intervention: Protected lungs (stress index values within 0.95 to 1.05 range)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonprotected lungs (stress index values greater than 1.05 or less than 0.95)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Protected lungs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Stress index during EVLP
Number of subjects: 14
Study: 26425877

Group type: EXPERIMENTAL
Intervention: Pretransplant circulating CD4+CD127lo/-TNFR2+ Treg cells
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Percentage and absolute number of CD4+CD127lo/-TNFR2+ Treg cells
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pretransplant recipient circulating CD4+CD127lo/-TNFR2+ Treg cells
Number of subjects: 76
Study: 26426575

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 30
Study: 26427420

Group type: EXPERIMENTAL
Intervention: MERTK mutations
Number of subjects: 0
Study: 26427533

Group type: EXPERIMENTAL
Intervention: Perceived arm strength (SIS 1a)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Perceived grip strength (SIS 1b)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Dichotomized SIS (cut-off 80%)
Number of subjects: 99
Study: 26427534

Group type: EXPERIMENTAL
Intervention: Increased insulin resistance in men
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Increased insulin resistance in women
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Duration since diabetes diagnosis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 112
Study: 26427727

Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 26428249

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg BID)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 1154
Study: 26428319

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 1000 or 1500 mg/day (20 mg/kg/day, twice daily) and verapamil sustained-release tablets (120-240 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Xenograft studies with similar dosing of HU and verapamil
Number of subjects: 7
Study: 26428486

Group type: EXPERIMENTAL
Intervention: Fludarabine (30 mg/m(2)/day for 5 days on days -6 to -2) and melphalan (100 mg/m(2) on day -2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fludarabine and melphalan conditioning therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions
Number of subjects: 26
Study: 26428846

Group type: EXPERIMENTAL
Intervention: Stress hyperglycaemia during ICU stay
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: FINDRISC score
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: SAPS3 score
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Daily caloric intake during ICU stay
Number of subjects: 338
Study: 26428987

Group type: EXPERIMENTAL
Intervention: 8-gauge needle
Number of subjects: 160

Group type: COMPARATOR
Intervention: 15-gauge needle
Number of subjects: 160
Study: 26429100

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Web-assisted tobacco intervention
Number of subjects: 1214
Study: 26429135

Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution using the VolumeView™ system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulmonary artery continuous thermodilution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calibrated pulse contour analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uncalibrated pulse contour analysis
Number of subjects: 20
Study: 26429296

Group type: EXPERIMENTAL
Intervention: Trastuzumab (AC-TH)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide followed by paclitaxel (AC-T)
Number of subjects: 901
Study: 26429339

Group type: EXPERIMENTAL
Intervention: Clinician-supported inpatient self-managed insulin
Number of subjects: 336
Study: 26429745

Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment strategy for obstructive sleep apnea (OSA)
Number of subjects: 73
Study: 26429963

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 26430171

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 85
Study: 26430465

Group type: EXPERIMENTAL
Intervention: Vitamin-D group (48 μg of vitamin-D + 800 mg calcium)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (800 mg calcium)
Number of subjects: 40
Study: 26430892

Group type: EXPERIMENTAL
Intervention: Albuminuria (measured by urinary albumin-to-creatinine ratio, ACR)
Number of subjects: 1456

Group type: COMPARATOR
Intervention: ACR <30 mg/g (reference group)
Number of subjects: 1456
Study: 26431695

Group type: EXPERIMENTAL
Intervention: howRu questionnaire
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: howRwe questionnaire
Number of subjects: 90
Study: 26432008

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200mg/day
Number of subjects: 29
Study: 26432046

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg daily for the first 14 days of cycle 1 then continuously for subsequent cycles, combined with hyper-CVAD chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate, and cytarabine) every 21 days.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ponatinib maintenance 45 mg daily with vincristine and prednisone monthly for 2 years followed by ponatinib indefinitely.
Number of subjects: 37
Study: 26432420

Group type: EXPERIMENTAL
Intervention: Antipsychotic treated SCZs
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Antipsychotic free SCZs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SCZ smokers
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SCZ nonsmokers
Number of subjects: 25
Study: 26432721

Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization (HCR)
Number of subjects: 100
Study: 26433580

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.1 mg/m(2) (moderate impairment)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 0.7 mg/m(2) (severe impairment)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m(2) (normal renal function)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Simulated dose reduction to eribulin 1.1 mg/m(2) (moderate/severe renal impairment)
Number of subjects: 19

Group type: COMPARATOR
Intervention: All groups (normal, moderate, severe)
Number of subjects: 19
Study: 26434510

Group type: EXPERIMENTAL
Intervention: CTO percutaneous coronary intervention techniques
Number of subjects: 0
Study: 26435425

Group type: EXPERIMENTAL
Intervention: Parathyroid adenomectomy (PTX)
Number of subjects: 150
Study: 26435832

Group type: EXPERIMENTAL
Intervention: Increased structural covariance among subcortical regions and between subcortical and cortical regions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Striatum and amygdala involvement
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Structural associations specific to IS
Number of subjects: 55
Study: 26435889

Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES) applied via electrodes on the ear for 1 hour daily
Number of subjects: 167

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 167
Study: 26436130

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg per day (initially), later reduced to 30 mg or 15 mg per day due to tolerability issues, with aspirin 81 mg daily.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ponatinib treatment (overall), with dose adjustments and monitoring.
Number of subjects: 51
Study: 26436448

Group type: EXPERIMENTAL
Intervention: ABR regimen (alemtuzumab, belatacept, and rapamycin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional immunosuppression
Number of subjects: 30
Study: 26437217

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSAs)
Number of subjects: 354
Study: 26437664

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) as a covariate in ANCOVA models
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Lower levels of MVPA
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 1122
Study: 26438146

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 2233

Group type: COMPARATOR
Intervention: Usual care or usual care plus cancer educational materials (Control)
Number of subjects: 2233
Study: 26438201

Group type: EXPERIMENTAL
Intervention: Carotid artery intima media thickness assessment
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Presence of atheromatous plaque
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Diagnosis of subclinical atherosclerosis
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Correlation with UKPDS and Framingham risk scores
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Prevalence of subclinical atherosclerosis in low risk group
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Increased waist circumference and longer diabetes duration
Number of subjects: 355
Study: 26438349

Group type: EXPERIMENTAL
Intervention: HIV counselling and testing services
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cervical cancer screening and HIV care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-natal care and HIV care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Family planning and sexually transmitted infection treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Integration of HIV and SRH services
Number of subjects: 40
Study: 26438497

Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Levofloxacin plus rifampin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus clindamycin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus amoxicillin-clavulanate
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Empirical antibiotic combination therapy
Number of subjects: 101
Study: 26438614

Group type: EXPERIMENTAL
Intervention: Sulfonylurea (SU) therapy
Number of subjects: 19
Study: 26438711

Group type: EXPERIMENTAL
Intervention: Deferred consent for emergency admissions (n = 1178)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Prospective consent for elective admissions (n = 641)
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Consent obtained for emergency admissions (n = 1298)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Non-consented patients (n = 314)
Number of subjects: 1358
Study: 26439129

Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine (IMVAMUNE), 2 doses subcutaneously, 4 weeks apart
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine (IMVAMUNE)
Number of subjects: 632
Study: 26439440

Group type: EXPERIMENTAL
Intervention: Maternal FADS2 genotype and DNA methylation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Arachidonic acid intake
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intake of 3 major n-3 species (eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Maternal FADS2 methylation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FADS2 genotype and DNA methylation in toddlers
Number of subjects: 65
Study: 26439886

Group type: EXPERIMENTAL
Intervention: Intracavernous autologous bone marrow-mononuclear cells (BM-MNCs) injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher doses of BM-MNCs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intracavernous autologous BM-MNC injection
Number of subjects: 12
Study: 26440706

Group type: EXPERIMENTAL
Intervention: Low dose arsenic trioxide (0.005 mg/kg/day for 3 days) administered before chemotherapy cycles 2, 4, and 6
Number of subjects: 26

Group type: COMPARATOR
Intervention: Chemotherapy cycles 1, 3, and 5 (baseline)
Number of subjects: 26
Study: 26441156

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control group (unexposed infants)
Number of subjects: 487
Study: 26441155

Group type: EXPERIMENTAL
Intervention: Youths with DBD and low levels of callous-unemotional traits
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Youths with DBD
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Youths with DBD and low callous-unemotional traits
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ventromedial prefrontal cortex-amygdala connectivity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dysfunctional ventromedial prefrontal cortex-amygdala connectivity
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy youths
Number of subjects: 56
Study: 26441187

Group type: EXPERIMENTAL
Intervention: Open Release Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic Release Surgery
Number of subjects: 0
Study: 26442234

Group type: EXPERIMENTAL
Intervention: Myofascial structural integration therapy (n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlist-Control (n=9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Parent surveys
Number of subjects: 29
Study: 26443344

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound (US) by senior physicians
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2 scan-fast exam (epigastrium and right hypochondrium)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Abdominal radiography
Number of subjects: 22

Group type: COMPARATOR
Intervention: Junior reviewers evaluating US
Number of subjects: 22
Study: 26444282

Group type: EXPERIMENTAL
Intervention: Anakinra (ANA) 100 mg daily for one year
Number of subjects: 17

Group type: COMPARATOR
Intervention: Historical cohort of 47 patients
Number of subjects: 17
Study: 26444662

Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TAG320
Number of subjects: 51

Group type: COMPARATOR
Intervention: CT coronary angiography alone
Number of subjects: 51
Study: 26445139

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg; positive control)
Number of subjects: 60
Study: 26445642

Group type: EXPERIMENTAL
Intervention: Benchmarking group
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 797
Study: 26445691

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 685
Study: 26445924

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 18 months
Number of subjects: 85
Study: 26446126

Group type: EXPERIMENTAL
Intervention: NREM sleep desaturation (NREMDes) patients (n = 59)
Number of subjects: 115
Study: 26446483

Group type: EXPERIMENTAL
Intervention: Plasma α-tocopherol concentrations
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Plasma γ-tocopherol concentrations
Number of subjects: 500
Study: 26446491

Group type: EXPERIMENTAL
Intervention: DJBL treatment
Number of subjects: 17
Study: 26446943

Group type: EXPERIMENTAL
Intervention: BRAF mutation-positive cfDNA
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Dabrafenib and Trametinib
Number of subjects: 732
Study: 26447149

Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Number of subjects: 2912

Group type: COMPARATOR
Intervention: Enteral Nutrition
Number of subjects: 2912
Study: 26447158

Group type: EXPERIMENTAL
Intervention: Serum retinol (SR) concentration adjusted for inflammation in Zambian children
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Marker-adjusted SR cutoffs of 0.6 μmol/L for late convalescence and 0.5 μmol/L for early convalescence
Number of subjects: 165

Group type: COMPARATOR
Intervention: Total liver reserves (TLRs)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Serum retinol (SR) concentrations
Number of subjects: 165
Study: 26447761

Group type: EXPERIMENTAL
Intervention: od-value thresholds for infarct size > 100 ml
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: od-value thresholds for infarct size > 70 ml
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: od-value compared to volumetric measures
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: od-value compared to visual estimations and ABC/2 method
Number of subjects: 108
Study: 26448169

Group type: EXPERIMENTAL
Intervention: Combination of substance P-derived peptide FGLM-amide and IGF-1-derived peptide SSSR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance P and insulin-like growth factor 1 (IGF-1)
Number of subjects: 0
Study: 26448724

Group type: EXPERIMENTAL
Intervention: Variable dose warfarin (first dose on the night preceding surgery with subsequent target INR 2.0-2.5)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily starting 6-18 h postoperatively
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Fixed 1.0 mg dose warfarin daily starting 7 days preoperatively
Number of subjects: 355

Group type: COMPARATOR
Intervention: Fixed low dose warfarin
Number of subjects: 355
Study: 26448868

Group type: EXPERIMENTAL
Intervention: Skeletal muscle citrate synthase (CS) activity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Maximal complex 2 driven mitochondrial respiration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 25
Study: 26448901

Group type: EXPERIMENTAL
Intervention: Oral QLT091001 administered once daily for 7 days
Number of subjects: 32
Study: 26449224

Group type: EXPERIMENTAL
Intervention: Combination therapy of temozolomide (TMZ) 150 mg/m² PO daily on days 1-5 and veliparib (ABT-888) 40 mg PO daily on days 1-7 of a 28-day cycle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination therapy of temozolomide (TMZ) and veliparib (ABT-888)
Number of subjects: 16